Pharma Focus Asia

MSD Invests US$1.18 billion (€1 billion) to Expand Footprint in Ireland

Introduction:

MSD invests US$1.18 billion (€1 billion) to expand its facilities in Dunboyne and Carlow, both situated in Ireland.

Features:

The new expansion is poised to enhance global manufacturing capacity significantly, allowing to effectively address the rising need for its medicines and vaccines worldwide.

These two facilities are set to deliver substantial improvements in manufacturing capabilities, thereby empowering the global network to effectively respond to the ever-evolving global demand for vaccines and medicines.

These new facilities will result in the generation of 100 new employment opportunities. These positions will encompass a diverse array of crucial roles, including engineering, scientific research, manufacturing operations, quality control, and various other vital functions.

Both the expansion in Carlow and the opening of the new MSD Dunboyne facility hold pivotal roles in MSD's global operations. Carlow site plays a crucial role for filling and commercial supply of vaccines, biologics, and small molecule drug products, facilitating their launch and distribution.

Specifications:

Name   MSD
Type   Expansion
Budget US$1.18 billion (€1 billion)
 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference